Ideally, clinical pathways can be a useful tool to help clinicians make sense of quickly evolving science, ensure patients receive the right care at the right time, help standardize care and limit unnecessary variation. But are these pathways working as intended?
To understand how oncology pathways can meet their potential in supporting patient access to optimal care, the Turning the Tide Against Cancer (T3) initiative convened a multidisciplinary expert working group, which included National Pharmaceutical Council Vice President of Health Services Research Kimberly Westrich, MA, to develop consensus around the critical elements that pathways must have to deliver high-quality and high-value oncology care. The research that informed that working group’s conversations found that clinical care pathways lack transparency and patient engagement while increasing the burden on care providers, and that a lack of oversight is proving problematic in pathway implementation. The T3 initiative resulted in a set of best practices that recommended identifying an independent third party that could serve in an accreditation or oversight capacity, and could be tasked with developing standards and measures for each part of the pathway phase, from development to monitoring and evaluation.
Ms. Westrich will serve as a panelist for a free online webinar, “Oncology Clinical Pathways: Making Treatment Decisions in the Era of Patient-Centered, Personalized Cancer Care” to discuss the findings and recommendations from the white paper. The webinar, which will be held on Monday, June 12, from 12 p.m.-1 p.m., will offer insight from experts in the patient advocacy, research and clinical care communities. Visit our Events page to learn more.